FDA Approves Baxdrostat for Resistant Hypertension - Summary - MDSpire

FDA Approves Baxdrostat for Resistant Hypertension

  • By

  • Kathryn Wighton

  • May 18, 2026

Share

Objective:

To evaluate the efficacy of baxdrostat in treating resistant hypertension in adults with uncontrolled blood pressure despite existing antihypertensive therapies.

Key Findings:
  • Baxdrostat 2 mg resulted in a 15.7 mmHg reduction in seated systolic blood pressure from baseline, corresponding to a 9.8 mmHg placebo-adjusted reduction.
  • Baxdrostat 1 mg led to a 14.5 mmHg reduction from baseline, with an 8.7 mmHg placebo-adjusted reduction.
  • The placebo group showed a 5.8 mmHg reduction in seated systolic blood pressure.
  • Baxdrostat selectively inhibits aldosterone synthase without affecting cortisol levels.
Interpretation:

The significant reductions in blood pressure with baxdrostat suggest it may be an effective treatment option for patients with resistant hypertension, potentially reducing the risk of serious cardiovascular events.

Limitations:
  • The study duration was limited to 12 weeks, which may not fully capture long-term efficacy and safety.
  • The trial population may not represent all demographics affected by resistant hypertension, particularly in terms of age, ethnicity, and comorbid conditions.
Conclusion:

Baxdrostat is the first aldosterone synthase inhibitor approved for resistant hypertension, offering a new therapeutic option for patients with uncontrolled blood pressure.

Original Source(s)

FDA Approves Baxdrostat for Resistant Hypertension

  • by Kathryn Wighton

  • May 18, 2026

Related Content

Non-Invasive Testing for Coronary Artery Disease

Dr. Uprety discusses the current role of non-invasive testing for coronary artery disease, highlighting evidence-based diagnostic strategies and the appropriate use of imaging modalities to improve early detection, risk stratification, and clinical decision-making.

  • May 18, 2026

Non-Invasive Techniques In Pediatric Dyslipidemia

Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.

  • by

  • May 15, 2026

  • 1 min
LV Function Mostly Preserved After ASO

CMR findings were largely reassuring in most patients, although late gadolinium enhancement was identified in a minority